Intellectual Property,
Health Care & Hospital Law,
Civil Litigation
Mar. 23, 2020
Illumina wins appeals court reversal of DNA test patent ruling
A federal circuit opinion overturned the U.S. District Court’s order invalidating Illumina Inc.’s two pre-natal DNA testing patents in an infringement dispute against Ariosa Diagnostics, Inc.
In a 2-1 opinion, the U.S. Court of Appeals for the Federal Circuit reversed a trial court's order invalidating two patent claims involving prenatal DNA tests based on an ineligible natural phenomenon.
The two companies involved, plaintiff Illumina Inc. and defendant Ariosa Diagnostics Inc., make competing prenatal tests that screen for genetic flaws using noninvasive techniques and reducing risks associated with amniocentesis.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In